<DOC>
	<DOCNO>NCT03049852</DOCNO>
	<brief_summary>1 . CBT-001 administer three time daily ( TID ) 4 week acceptable safety profile use pterygium patient 2 . CBT-001 administer TID 4 week effective vehicle reduce pterygium vascularity inhibit pterygium lesion growth 3 . CBT-001 administered topical ocular dosing display negligible systemic drug exposure</brief_summary>
	<brief_title>Safety Efficacy CBT-001 Ophthalmic Solution Patients With Pterygium</brief_title>
	<detailed_description />
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Primary pterygium moderate vascularity ( Pterygium Hyperemia Grading Scale â‰¥ 3 ) Active ocular disease , corneal abnormality pterygium , active ocular infection , ocular pathology unrelated pterygium either eye could affect assessment pterygium History ocular herpes disease either eye Any ocular surgical procedure within last 3 month Female patient pregnant , nursing , plan pregnancy study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>